American Journal of Cardiology
Volume 95, Issue 6 , Pages 716-721 , 15 March 2005

Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center

Received 2 September 2004 ,Accepted 18 November 2004.

References 

  1. The EPIC Investigation . EPIC (Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty) . N Engl J Med . 1994;330:956–961
  2. The EPILOG Investigators . EPILOG (Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization) . N Engl J Med . 1997;336:1689–1696
  3. The EPISTENT Investigators . EPISTENT (Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting) . Lancet . 1998;352:87–92
  4. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization . Am J Med . 2002;113:1–6
  5. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial . JAMA . 2003;289:853–863
  6. Ellis SG , Guetta V , Miller D , Whitlow PL , Topol EJ . Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: an analysis of results from 10,907 lesions and proposal for new classification scheme . Circulation . 1999;100:1971–1976
  7. D'Agostino RB . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group . Stat Med . 1998;17:2265–2281
  8. Hirsh J . Heparin . N Engl J Med . 1991;324:1565–1574
  9. Eitzman DT , Chi L , Saggin L , Schwartz RS , Lucchesi BR , Fay WP . Heparin neutralization by platelet-rich thrombi (Role of platelet factor 4) . Circulation . 1994;89:1523–1529
  10. Xiao Z , Theroux P . Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor . Circulation . 1998;97:251–256
  11. Weitz JI , Hudoba M , Massel D , Maraganore J , Hirsh J . Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III–independent inhibitors . J Clin Invest . 1990;86:385–391
  12. Aggarwal A , Sobel BE , Schneider DJ . Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention . J Thromb Thrombolysis . 2002;13:161–165
  13. Witting JI , Bourdon P , Brezniak DV , Maraganore JM , Fenton JW . Thrombin-specific inhibition by and slow cleavage of hirulog-1 . Biochem J . 1992;283(pt 3):737–743
  14. Parry MA , Maraganore JM , Stone SR . Kinetic mechanism for the interaction of Hirulog with thrombin . Biochemistry . 1994;33:14807–14814

PII: S0002-9149(04)01874-0

doi: 10.1016/j.amjcard.2004.11.021

American Journal of Cardiology
Volume 95, Issue 6 , Pages 716-721 , 15 March 2005

Article Tools

* Image Usage & Resolution